Navigation Links
Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron

BILLERICA, Massachusetts --- June 20, 2007 --- Millipore Corporation today announced the release of new data concerning its ReNcell neural stem cell lines. The research was conducted by the Department of Physiology at University College London and ReNeuron Group plc, whose ReNcell distribution agreement with Millipore was announced in 2006. The data will be presented by Dr. Vi Chu, research & development scientist for Millipore’s Bioprocess Division, in a technology talk at the ISSCR meeting in Cairns, Australia on June 20, 2007.

The data conclude that the ReNcell lines, ReNcell VM and ReNcell CX, will continuously expand in monolayer culture. Both cell lines have the ability to differentiate into neurons, astrocytes and oligodendrocytes, and the researchers were able to differentiation the ReNcell VM line into electrophysiologically active dopaminergic neurons. The study was published in the May edition of BMC Neuroscience and may be read in its entirety at: www.biomedcentral.com/1471-2202/8/36/abstract.

The ReNcell neural stem cell lines are immortalized human neural progenitor cells that have the ability to readily differentiate into neural cell types and will replicate indefinitely. ReNcell immortalized cells display the same marker patterns as normal cells and are able to grow and remain stable after culturing. These cells are important tools for the discovery of new therapies targeting diseases of the central nervous system.

Millipore’s Bioscience Division provides innovative tools, services and biological reagents that drive advancements in biomedical and academic research as well as support the discovery and development of new pharmaceuticals. The product portfolio has been further enhanced with the 2006 addition of Chemicon, Upstate and Linco product lines, allowing Millipore to provide the most complete offering of life science tools on the market. Our customers work in leading research laboratories across a variety of industries throughout the world. Millipore improves their laboratory productivity and efficiency through optimized workflows. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.

###

About Millipore

Millipore is a leading provider of products and services that improve productivity in biopharmaceutical manufacturing and in clinical, analytical and research laboratories. The Company is organized in two operating divisions. Its Bioprocess Division helps enables pharmaceutical and biotechnology companies to optimize their manufacturing productivity, ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics. Its Bioscience division helps to optimize laboratory productivity and workflows. Its products and enabling technologies that are used in the laboratory are esse ntial for the research and development of biologically based life science therapeutics. Millipore has a deep understanding of its customers’ research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company is part of the S&P 500 index and employs approximately 5,800 employees in more than 47 offices worldwide. For additional information on Millipore Corporation, please visit its website at: www.millipore.com.

About ReNeuron Group plc

ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. The Group has also leveraged their stem cell technologies into non-therapeutic areas such as drug discovery. ReNeuron was founded in 1997 to commercialize technology discovered by its founding scientists working at the Institute of Psychiatry, Kings College London. ReNeuron currently employs around 30 staff, including 15PhDs, with many years combined experience in stem cell research and development. ReNeuron operates form state-of-the-art laboratories in Guildford, Surrey, UK, which are fitted out to meet the stringent requirements of the regulatory authorities for cell therapy products. For additional information on ReNeuron, please visit its website at: www.reneuron.com.

Millipore is a registered trademark of Millipore Corporation. ReNcell is a registered trademark of ReNeuron Group plc.

Media Contact:

Lauren Nolan

Communications Specialist

Millipore Corporation

978-762-5080

lauren_nolan@millipore.com


'"/>




Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
3. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
4. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):